Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy

Background: Our objectives were to evaluate the temporal changes in CMR-based strain imaging, and examine their relationship with left ventricular ejection fraction (LVEF), in patients treated with trastuzumab. Patients and methods: In this prospective longitudinal observational study, 41 women with HER2+ breast cancer treated with chemotherapy underwent serial CMR (baseline, 6, 12, and 18 months) after initiation of trastuzumab (treatment duration 12 months). LVEF and LV strain (global longitudinal[GLS] and circumferential[GCS]) measurements were independently measured by 2 blinded readers. Results: Of the 41 patients, 56% received anthracycline-based chemotherapy. Compared to baseline (60.4%, 95% CI 59.2-61.7%), there was a small but significant reduction in LVEF at 6 months (58.4%, 95% CI 56.7-60.0%, p = 0.034) and 12 months (57.9%, 95% CI 56.4-59.7%, p= 0.012), but not at 18 months (60.2%, 95% CI 58.2-62.2%, p = 0.93). Similarly, compared to baseline, GLS and GCS decreased significantly at 6 months (p = 0.024 and < 0.001, respectively) and 12 months (p = 0.002 and < 0.001, respectively) with an increase in LV end diastolic volume, but not at 18 months. There were significant correlations between the temporal (6 monthbaseline) changes in LVEF, and all global strain measurements (Pearson's r=-0.60 and r=-0.75 for GLS and GCS, respectively, all p < 0.001). Conclusion: There was a significant reduction in LV strain during trastuzumab treatment, which correlated with a concurrent subtle decline in LVEF and was associated with an increase in LV end-diastolic volume. LV strain assessment by CMR may be a promising method to monitor for subclinical myocardial dysfunction in breast cancer patients receiving chemotherapy. Future studies are needed to determine its prognostic and therapeutic implications. (C) 2018 Elsevier B.V. All rights reserved.